Business Context and Reporting Period
This Form 8-K Current Report is filed by Safe & Green Holdings Corp. (not Olenox Industries Inc.) for the reporting date of April 14, 2025. The filing details the consummation of a previously announced private placement of equity securities.
Key Financial Metrics
- Gross Proceeds: Approximately $8.0 million.
- Net Proceeds: Approximately $6.6 million (after deducting placement agent fees and offering expenses).
- Offering Price: $0.392 per Common Unit.
- Transaction Structure: Sale of Common Units consisting of one share of Common Stock (or Pre-Funded Warrant), one Series A Warrant, and one Series B Warrant.
- Warrant Exercise Prices: Series A at $0.784 per share; Series B at $0.98 per share.
- Transaction Costs: 6.0% commission to D. Boral Capital LLC, 1.0% for non-accountable expenses, and 5.0% commission to Aegis Capital Corp.
Material Changes
The primary material change is the increase in cash liquidity resulting from the private placement. The filing does not provide comparative financial data (e.g., revenue, profit, or debt levels) for prior periods as this is a current event report rather than a periodic financial statement.
Guidance, Outlook, and Risks
- Use of Proceeds: The filing does not explicitly state the specific use of proceeds in the text provided, though the transaction was priced at the market under Nasdaq rules.
- Regulatory Requirements: The Company entered into a Registration Rights Agreement requiring the filing of a registration statement for the resale of securities by April 30, 2025.
- Warrant Conditions: Series A and Series B Warrants are exercisable only following stockholder approval. Series A Warrants expire in 5 years; Series B Warrants expire in 2.5 years.
- Dilution Risk: The issuance of warrants and pre-funded warrants introduces potential future dilution to existing shareholders.
Investor Verification Checklist
- Verify the exact number of shares and warrants issued to confirm total dilution impact.
- Confirm the status of the required registration statement filing by the April 30, 2025 deadline.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Check for the outcome of the required stockholder approval for warrant exercisability.
- Clarify the specific intended use of the $6.6 million in net proceeds, as it is not detailed in this summary text.